Tuberculosis and Respiratory Diseases

  • 제86권3호
  • /
  • Pages.158-165
  • /
  • 2023
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지
DOI QR코드

DOI QR Code

Summary of Korean Asthma Guideline

  • Chin Kook Rhee (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Ji-Yong Moon (Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine) ;
  • Hyonsoo Joo (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Ji Ye Jung (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine) ;
  • Jung-Kyu Lee (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center) ;
  • Kyung Hoon Min (Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine) ;
  • Hyeon-Kyoung Koo (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Inje University Ilsan Paik Hospital, College of Medicine, Inje University) ;
  • Seong Yong Lim (Division of Pulmonary and Critical Care Medicine, Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Hyoung Kyu Yoon (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Sang Yeub Lee (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine) ;
  • The Korean Academy of Tuberculosis and Respiratory Diseases (KATRD) (The Korean Academy of Tuberculosis and Respiratory Diseases (KATRD))
  • 투고 : 2023.04.11
  • 심사 : 2023.05.26
  • 발행 : 2023.07.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Asthma is a chronic inflammatory airway disease that is characterized by variable airflow obstruction. The Korean Asthma Study Group of the Korean Academy of Tuberculosis and Respiratory Diseases has recently updated the Korean Asthma Guideline. This review summarizes the updated Korean Asthma Guideline. Asthma prevalence is increasing worldwide, and in Korea. Variable airflow obstruction can be confirmed by bronchodilator response or other tests, and should be established prior to the controller medication. A low-dose inhaled corticosteroid-formoterol is used to alleviate symptoms in all treatment step, and it can be used as a controller as well as reliever in steps 3-5. This approach is preferred, because it reduces the risk of severe exacerbations, compared to the use of short-acting β2-agonist as reliever. In severe asthma, phenotype/endotype based on the underlying inflammation should be evaluated. For type 2 severe asthma, the biologics should be considered.

키워드

참고문헌

  1. Lee JH, Kim JY, Choi JS, Na JO. Respiratory reviews in asthma 2022. Tuberc Respir Dis (Seoul) 2022;85:283-8. https://doi.org/10.4046/trd.2022.0097
  2. Kim DK, Park YB, Oh YM, Jung KS, Yoo JH, Yoo KH, et al. Korean Asthma Guideline 2014: summary of major updates to the Korean Asthma Guideline 2014. Tuberc Respir Dis (Seoul) 2016;79:111-20. https://doi.org/10.4046/trd.2016.79.3.111
  3. Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, et al. Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes. Am J Respir Crit Care Med 2022;205:17-35. https://doi.org/10.1164/rccm.202109-2205PP
  4. Choi JY, Yoon HK, Lee JH, Yoo KH, Kim BY, Bae HW, et al. Current status of asthma care in South Korea: nationwide the Health Insurance Review and Assessment Service database. J Thorac Dis 2017;9:3208-14. https://doi.org/10.21037/jtd.2017.08.109
  5. Kitch BT, Paltiel AD, Kuntz KM, Dockery DW, Schouten JP, Weiss ST, et al. A single measure of FEV1 is associated with risk of asthma attacks in long-term follow-up. Chest 2004;126:1875-82. https://doi.org/10.1378/chest.126.6.1875
  6. Osborne ML, Pedula KL, O'Hollaren M, Ettinger KM, Stibolt T, Buist AS, et al. Assessing future need for acute care in adult asthmatics: the Profile of Asthma Risk Study: a prospective health maintenance organization-based study. Chest 2007;132:1151-61. https://doi.org/10.1378/chest.05-3084
  7. Fuhlbrigge AL, Kitch BT, Paltiel AD, Kuntz KM, Neumann PJ, Dockery DW, et al. FEV(1) is associated with risk of asthma attacks in a pediatric population. J Allergy Clin Immunol 2001;107:61-7. https://doi.org/10.1067/mai.2001.111590
  8. Li D, German D, Lulla S, Thomas RG, Wilson SR. Prospective study of hospitalization for asthma: a preliminary risk factor model. Am J Respir Crit Care Med 1995;151(3 Pt 1):647-55. https://doi.org/10.1164/ajrccm/151.3_Pt_1.647
  9. Jo YS, Hwang YI, Yoo KH, Kim TH, Lee MG, Lee SH, et al. Effect of inhaled corticosteroids on exacerbation of asthma-COPD overlap according to different diagnostic criteria. J Allergy Clin Immunol Pract 2020;8:1625-33. https://doi.org/10.1016/j.jaip.2020.01.004
  10. Bateman ED, Reddel HK, O'Byrne PM, Barnes PJ, Zhong N, Keen C, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med 2018;378:1877-87. https://doi.org/10.1056/NEJMoa1715275
  11. O'Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med 2018;378:1865-76. https://doi.org/10.1056/NEJMoa1715274
  12. Beasley R, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med 2019;380:2020-30. https://doi.org/10.1056/NEJMoa1901963
  13. Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet 2019;394:919-28. https://doi.org/10.1016/S0140-6736(19)31948-8
  14. Beasley R, Braithwaite I, Semprini A, Kearns C, Weatherall M, Harrison TW, et al. ICS-formoterol reliever therapy stepwise treatment algorithm for adult asthma. Eur Respir J 2020;55:1901407.
  15. Papi A, Corradi M, Pigeon-Francisco C, Baronio R, Siergiejko Z, Petruzzelli S, et al. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Lancet Respir Med 2013;1:23-31. https://doi.org/10.1016/S2213-2600(13)70012-2
  16. Patel M, Pilcher J, Pritchard A, Perrin K, Travers J, Shaw D, et al. Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir Med 2013;1:32-42. https://doi.org/10.1016/S2213-2600(13)70007-9
  17. Bateman ED, Harrison TW, Quirce S, Reddel HK, Buhl R, Humbert M, et al. Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. Respir Res 2011;12:38.
  18. Kew KM, Karner C, Mindus SM, Ferrara G. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev 2013;2013:CD009019.
  19. Manser R, Reid D, Abramson M. Corticosteroids for acute severe asthma in hospitalised patients. Cochrane Database Syst Rev 2001;1:CD001740.
  20. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J 2000;16:432-6. https://doi.org/10.1034/j.1399-3003.2000.016003432.x
  21. Swierczynska-Krepa M, Sanak M, Bochenek G, Strek P, Cmiel A, Gielicz A, et al. Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study. J Allergy Clin Immunol 2014;134:883-90. https://doi.org/10.1016/j.jaci.2014.02.041
  22. Murphy VE, Gibson PG. Asthma in pregnancy. Clin Chest Med 2011;32:93-110. https://doi.org/10.1016/j.ccm.2010.10.001
  23. Lim A, Stewart K, Konig K, George J. Systematic review of the safety of regular preventive asthma medications during pregnancy. Ann Pharmacother 2011;45:931-45. https://doi.org/10.1345/aph.1P764
  24. Wendel PJ, Ramin SM, Barnett-Hamm C, Rowe TF, Cunningham FG. Asthma treatment in pregnancy: a randomized controlled study. Am J Obstet Gynecol 1996;175:150-4. https://doi.org/10.1016/S0002-9378(96)70265-X
  25. Schatz M, Leibman C. Inhaled corticosteroid use and outcomes in pregnancy. Ann Allergy Asthma Immunol 2005;95:234-8. https://doi.org/10.1016/S1081-1206(10)61219-7
  26. Stenius-Aarniala B, Poussa T, Kvarnstrom J, Gronlund EL, Ylikahri M, Mustajoki P. Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study. BMJ 2000;320:827-32. https://doi.org/10.1136/bmj.320.7238.827
  27. Adeniyi FB, Young T. Weight loss interventions for chronic asthma. Cochrane Database Syst Rev 2012;7:CD009339.
  28. Shaaban R, Zureik M, Soussan D, Neukirch C, Heinrich J, Sunyer J, et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet 2008;372:1049-57. https://doi.org/10.1016/S0140-6736(08)61446-4
  29. Pauwels R. Influence of treatment on the nose and/or the lungs. Clin Exp Allergy 1998;28 Suppl 2:37-40.
  30. Adams RJ, Fuhlbrigge AL, Finkelstein JA, Weiss ST. Intranasal steroids and the risk of emergency department visits for asthma. J Allergy Clin Immunol 2002;109:636-42. https://doi.org/10.1067/mai.2002.123237